Showing 73 to 84 of 92 results
2025: A New Era of Private Lunar Missions
Multiple private companies are launching lunar missions in 2025, including Intuitive Machines' second attempt, Firefly Aerospace's Blue Ghost mission to collect soil samples, and Ispace's Resilience mission carrying a rover and artwork, marking a new phase in commercial space exploration.
2025: A New Era of Private Lunar Missions
Multiple private companies are launching lunar missions in 2025, including Intuitive Machines' second attempt, Firefly Aerospace's Blue Ghost mission to collect soil samples, and Ispace's Resilience mission carrying a rover and artwork, marking a new phase in commercial space exploration.
Progress
32% Bias Score
Colossal Biosciences Secures \$200 Million in Funding, Valued at \$10.2 Billion
Colossal Biosciences, a company working to revive extinct species like the woolly mammoth, secured \$200 million in Series C funding, bringing its total funding to \$435 million and valuing the company at \$10.2 billion. The company plans to use the funds to advance genetic engineering technologies ...
Colossal Biosciences Secures \$200 Million in Funding, Valued at \$10.2 Billion
Colossal Biosciences, a company working to revive extinct species like the woolly mammoth, secured \$200 million in Series C funding, bringing its total funding to \$435 million and valuing the company at \$10.2 billion. The company plans to use the funds to advance genetic engineering technologies ...
Progress
44% Bias Score
2024 Scientific Breakthroughs: Hope and Challenges for Humanity
2024 witnessed remarkable scientific progress in diverse fields, including AI, renewable energy, genetic engineering, and medicine, offering solutions to global issues like disease, hunger, and climate change, but also raising ethical concerns.
2024 Scientific Breakthroughs: Hope and Challenges for Humanity
2024 witnessed remarkable scientific progress in diverse fields, including AI, renewable energy, genetic engineering, and medicine, offering solutions to global issues like disease, hunger, and climate change, but also raising ethical concerns.
Progress
48% Bias Score
Biotech's Binary Week: Mesoblast Soars, Percheron Crashes
In the final week of 2023, contrasting fortunes played out in the Australian biotech sector as Mesoblast shares soared 50% following US FDA approval, while Percheron shares crashed over 90% after a failed drug trial, highlighting the high-risk, high-reward nature of the industry.
Biotech's Binary Week: Mesoblast Soars, Percheron Crashes
In the final week of 2023, contrasting fortunes played out in the Australian biotech sector as Mesoblast shares soared 50% following US FDA approval, while Percheron shares crashed over 90% after a failed drug trial, highlighting the high-risk, high-reward nature of the industry.
Progress
60% Bias Score
Kenya Holds Public Forums on GM Bt Maize Release
Kenya's National Biosafety Authority (NBA) is conducting public forums next week in four counties to gather input on the potential release of genetically modified Bt maize, submitted by KALRO and AATF, to combat fall armyworms and maize stem borers, following biosafety regulations.
Kenya Holds Public Forums on GM Bt Maize Release
Kenya's National Biosafety Authority (NBA) is conducting public forums next week in four counties to gather input on the potential release of genetically modified Bt maize, submitted by KALRO and AATF, to combat fall armyworms and maize stem borers, following biosafety regulations.
Progress
32% Bias Score
2024: A Year of Technological Milestones and Challenges
2024 witnessed AI's significant impact on global elections, breakthroughs in sustainability tech, space exploration milestones (SpaceX's Starship landing and India's moon landing), and record-breaking quantum computing achievements, alongside the FDA approval of the first T-cell therapy for solid tu...
2024: A Year of Technological Milestones and Challenges
2024 witnessed AI's significant impact on global elections, breakthroughs in sustainability tech, space exploration milestones (SpaceX's Starship landing and India's moon landing), and record-breaking quantum computing achievements, alongside the FDA approval of the first T-cell therapy for solid tu...
Progress
44% Bias Score
AI Boosts Cellular Reprogramming Efficiency 50-Fold
OpenAI and Retro Biosciences developed GPT-4b, an AI model boosting the efficiency of Yamanaka proteins, key to cellular reprogramming, by 50 times in early tests, paving the way for new disease treatments.
AI Boosts Cellular Reprogramming Efficiency 50-Fold
OpenAI and Retro Biosciences developed GPT-4b, an AI model boosting the efficiency of Yamanaka proteins, key to cellular reprogramming, by 50 times in early tests, paving the way for new disease treatments.
Progress
36% Bias Score
AI Dominates \$100 Billion in Global Investments
At the 2025 Asian Financial Forum in Hong Kong, panelists highlighted AI's dominance in global investments, exceeding \$100 billion, with Saudi Arabia and Indonesia spearheading national AI strategies to boost their respective economies.
AI Dominates \$100 Billion in Global Investments
At the 2025 Asian Financial Forum in Hong Kong, panelists highlighted AI's dominance in global investments, exceeding \$100 billion, with Saudi Arabia and Indonesia spearheading national AI strategies to boost their respective economies.
Progress
36% Bias Score
Generative AI Revolutionizes Protein Design: Implications for Medicine and Future Pandemics
Geoff von Maltzahn of Flagship Pioneering discusses using generative AI to design proteins with precise functions, such as antibodies targeting viruses and creating new enzymes, highlighting the vast potential for biological discovery and its implications for human health and future pandemics.
Generative AI Revolutionizes Protein Design: Implications for Medicine and Future Pandemics
Geoff von Maltzahn of Flagship Pioneering discusses using generative AI to design proteins with precise functions, such as antibodies targeting viruses and creating new enzymes, highlighting the vast potential for biological discovery and its implications for human health and future pandemics.
Progress
48% Bias Score
Market Movers: Nordstrom Privatization, Novo Nordisk Rebound, and Tech MA
In midday trading, Nordstrom shares fell over 1% following its \$6.25 billion buyout, while Novo Nordisk shares rebounded after a previous drop; Honda surged over 11% on merger talks with Nissan; Xerox rose 7% on its Lexmark acquisition; Despegar.com soared 32% on Prosus's buyout; and Traws Pharma j...
Market Movers: Nordstrom Privatization, Novo Nordisk Rebound, and Tech MA
In midday trading, Nordstrom shares fell over 1% following its \$6.25 billion buyout, while Novo Nordisk shares rebounded after a previous drop; Honda surged over 11% on merger talks with Nissan; Xerox rose 7% on its Lexmark acquisition; Despegar.com soared 32% on Prosus's buyout; and Traws Pharma j...
Progress
16% Bias Score
Mexico Loses USMCA Dispute Over GM Corn Ban
A USMCA panel ruled against Mexico's ban on GM corn for human consumption, concluding that Mexico's measures lacked scientific basis and violated the trade agreement. Mexico must now allow imports or face sanctions, despite its efforts to protect its native corn.
Mexico Loses USMCA Dispute Over GM Corn Ban
A USMCA panel ruled against Mexico's ban on GM corn for human consumption, concluding that Mexico's measures lacked scientific basis and violated the trade agreement. Mexico must now allow imports or face sanctions, despite its efforts to protect its native corn.
Progress
56% Bias Score
Italian Researcher's Open-Source AI Rivals DeepMind's AlphaFold3
Gabriele Corso, a 25-year-old Italian researcher at MIT, developed Boltz-1, an open-source AI model for analyzing molecular interactions with accuracy matching DeepMind's AlphaFold3, revolutionizing drug discovery by making advanced AI accessible to researchers worldwide.
Italian Researcher's Open-Source AI Rivals DeepMind's AlphaFold3
Gabriele Corso, a 25-year-old Italian researcher at MIT, developed Boltz-1, an open-source AI model for analyzing molecular interactions with accuracy matching DeepMind's AlphaFold3, revolutionizing drug discovery by making advanced AI accessible to researchers worldwide.
Progress
40% Bias Score
Showing 73 to 84 of 92 results